Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_assertion type Assertion NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_head.
- NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_assertion description "[Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 � 5.1 days) compared with pVAX-CDPK1 (17.3 � 4.3 days) or pVAX-IL-21-IL-15 (12.0 � 2.0 days) alone, and pVAX-IL-21-IL-15 +?pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_provenance.
- NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_assertion evidence source_evidence_literature NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_provenance.
- NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_assertion SIO_000772 25192845 NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_provenance.
- NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_assertion wasDerivedFrom befree-2016 NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_provenance.
- NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_assertion wasGeneratedBy ECO_0000203 NP1217318.RAcMG699FK7SQgnqaMg9Hbv1vWV2Klt448de5bO7qCXck130_provenance.